- SU-6656, a selective Src-kinase inhibitor.
- Ro 32-0432 Hydrochloride, a selective GRK-5 receptor (G protein-coupled receptor kinase-5 enzyme) Inhibitor.
- Ammonium Pyrrolidine Dithiocarbamate (APD), a selective Nuclear Factor kappa-B (NF-κB) inhibitor.
- RS 102895, a selective CCR-2 Chemokine receptor antagonist.
- FTI-276 Trifluoroacetate, a selective inhibitor of Farnesyltransferase subtype I
- Withdrawal syndrome was quantitatively assessed in vivo.
- Src-kinase, Farnesyltransferase subtype I, G protein-coupled receptor kinase-5 enzyme, Nuclear Factor kappa-B & CCR-2 Chemokine receptor, might serve as a viable pharmacological targets to tackle the problem of nicotine addiction.